Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
These findings highlight a previously underrecognized gut microbiotahormone axis and support a microbiota-guided approach to optimize GLP-1-based therapies for MASLD
Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
Some people who have nerve damage from a spinal cord injury, chemotherapy, or other diseases may have muscle cramps
and one stand-alone OA trial (TRIUMPH-4)
injections of 100 nmol kg 1 PYY analogue ( n = 7 mice and n = 6 cages), 100 nmol kg 1 PYYMK-801 ( n = 7 mice and n = 4 cages), 100 nmol kg 1 GLP-1MK-801 ( n = 7 mice and n = 5 cages) or vehicle (isotonic saline, n = 7 mice and n = 4 cages) for 6 days
Bile duct obstruction: Helps detect conditions like gallstones, inflammation of the bile duct, cysts in the bile ducts, etc., that increase GGT levels when there is blockage in the bile duct, often before other liver enzymes
